Brazil drug market seen reaching $42.21B by 2035

Brazil’s pharmaceutical industry is projected to grow from $34.4 billion in 2025 to $42.21 billion by 2035, according to Market Research Future. Rising chronic disease rates, generic-drug adoption and government support for local manufacturing are the main drivers behind the outlook.

Why it matters: - Brazil is the largest pharmaceutical market in Latin America, so its growth affects drug access, manufacturing investment and treatment availability across the region. - The forecast points to steady demand rather than rapid expansion, but the market’s size makes even modest growth meaningful for global and local drugmakers. - Chronic disease burden, aging demographics and policy support are reinforcing demand for long-term therapies.

What happened: - Market Research Future projected Brazil’s pharmaceutical industry market will rise from $34.4 billion in 2025 to $42.21 billion by 2035. - The report said the market base was $33.63 billion in 2024. - The forecast implies a 2.09% compound annual growth rate from 2025 to 2035. - The report highlighted rising chronic disease prevalence, generic-drug expansion and aging population trends as the main growth drivers. - The source material was published Aug. 25, 2026. - Request a free sample - Ask for customization - Read the full report

The details: - Noncommunicable diseases account for about 74% of all deaths in Brazil, according to the World Health Organization. - Pan American Health Organization data puts NCDs at nearly 75% of deaths in Brazil. - Generic drugs make up about 40% of the Brazilian pharmaceutical market. - Generic medicines can cut treatment costs by 30% to 80% versus branded alternatives, according to PubMed. - More than 30% of Brazil’s population is projected to be age 60 or older by 2025. - Healthcare spending equals about 9% of Brazil’s GDP. - Local production now represents about 60% of the pharmaceutical market. - ANVISA is modernizing biologics and regulatory pathways, which is streamlining approvals for new drugs and therapies.

Between the lines: - The market structure is shifting toward cheaper and more accessible medicines, which should help volume growth even if pricing remains under pressure. - Government support for domestic production and regulatory modernization suggests Brazil wants less reliance on imports and faster access to innovative therapies. - The report’s segment data shows where demand is concentrated: cardiovascular medicines lead, while oncology is growing fastest. - The competitive field remains moderately fragmented, which can leave room for both multinational drugmakers and local manufacturers to win share. - Some of the report’s company milestones, including partnerships, platform launches and factory expansion, point to a broader push into digital health and advanced therapies.

What's next: - The report expects stronger demand for telepharmacy, personalized medicine, digital health platforms, biologics and biosimilars through 2035. - Local manufacturing expansion should continue as tax incentives, funding and multinational partnerships support supply-chain stability. - Brazil’s drug market should keep benefiting from the scale of the public health system and from rising private insurance coverage.

The bottom line: - Brazil’s pharmaceutical market is on a slow but durable growth path, powered by chronic disease, aging and a shift toward generics and domestic production.